{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:00:14Z","timestamp":1780686014933,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The renin-angiotensin system (RAS) plays a central role in regulating blood pressure and has recently been implicated in cancer biology. Although angiotensin II (AngII) receptor blockers (ARBs) have shown clinical benefit in bladder cancer, their mechanisms of action remain unclear. Here, we investigated the contribution of AngII type 1 receptor (AGTR1) to bladder cancer progression and assessed the therapeutic potential of the ARB losartan (LOS). In patients with primary non-muscle-invasive bladder cancer, intravesical recurrence following transurethral tumor resection correlated with AGTR1 expression levels. Public database analysis revealed that the expression of AGTR1 and its downstream kinases, extracellular signal-regulated kinase (ERK) 1 and ERK2, was associated with overall survival in bladder urothelial carcinoma. In AGTR1-overexpressing T24 bladder cancer cells, AngII promoted invasion and migration and upregulated neuronal nitric oxide synthase, without affecting proliferation. These effects were accompanied by rapid ERK phosphorylation alongside Akt dephosphorylation. RNA sequencing revealed that AGTR1 expression and AngII stimulation activated NF-\u03baB, mTOR, and epithelial-mesenchymal transition (EMT) pathways. LOS suppressed these AngII-mediated responses, whereas the AngII-independent upregulation of EMT-related proteins and the enhancement of mitochondrial energy metabolism by AngII in AGTR1-overexpressing cells remained unaffected. In vivo, AGTR1 facilitated early tumor engraftment and promoted tumor progression, accompanied by reduced E-cadherin and elevated N-cadherin expression, with most of these changes suppressed by LOS treatment. In conclusion, our findings highlight the crucial role of AGTR1 in bladder cancer and support the repositioning of ARBs, such as LOS, as therapeutics for AGTR1-upregulated bladder cancer, while underscoring the importance of AGTR1 stratification for future clinical evaluation.<\/jats:p>","DOI":"10.1038\/s41440-025-02535-y","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:01:37Z","timestamp":1768784497000},"page":"1480-1494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan"],"prefix":"10.1038","volume":"49","author":[{"given":"Ryoken","family":"Yamanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megmi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anarkhuu","family":"Bold-Erdene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyanga","family":"Enkhbaatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Beygom","family":"Mirkatouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuka","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kobatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kohada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Hatayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yukihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Iwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kaminuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2535_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/j.2040-4603.2014.tb00567.x","volume":"4","author":"MA Sparks","year":"2014","unstructured":"Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201\u201328.","journal-title":"Compr Physiol"},{"key":"2535_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","volume":"21","author":"NS Wilcox","year":"2024","unstructured":"Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21:617\u201331.","journal-title":"Nat Rev Cardiol"},{"key":"2535_CR3","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1073\/pnas.0900351106","volume":"106","author":"DR Rhodes","year":"2009","unstructured":"Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 2009;106:10284\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2535_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbamcr.2016.03.010","volume":"1863","author":"E Oh","year":"2016","unstructured":"Oh E, Kim JY, Cho Y, An H, Lee N, Jo H, et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta. 2016;1863:1071\u201381.","journal-title":"Biochim Biophys Acta"},{"key":"2535_CR5","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.18632\/aging.102032","volume":"11","author":"Y Ma","year":"2019","unstructured":"Ma Y, Xia Z, Ye C, Lu C, Zhou S, Pan J, et al. AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4\/SDF-1\u03b1 and inducing cell migration and invasion. Aging (Albany NY). 2019;11:3969\u201392.","journal-title":"Aging (Albany NY)"},{"key":"2535_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08730-7","volume":"21","author":"ZW Qiao","year":"2021","unstructured":"Qiao ZW, Jiang Y, Wang L, Jiang J, Zhang JR, Mu P. LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression. BMC Cancer. 2021;21:1004.","journal-title":"BMC Cancer"},{"key":"2535_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.929979","volume":"10","author":"H Wang","year":"2022","unstructured":"Wang H, Cui Y, Gong H, Xu J, Huang S, Tang A. Suppression of AGTR1 induces cellular senescence in hepatocellular carcinoma through inactivating ERK signaling. Front Bioeng Biotechnol. 2022;10:929979.","journal-title":"Front Bioeng Biotechnol"},{"key":"2535_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.24976\/Discov.Med.202537193.32","volume":"37","author":"B Xie","year":"2025","unstructured":"Xie B, Gu Y, Li J, Wang H, Wang Y. Angiotensin II and AGTR1 in ESCC proliferation and invasion: insights from the JAK\/STAT3 pathway. Discov Med. 2025;37:394\u2013405.","journal-title":"Discov Med"},{"key":"2535_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3892\/etm_00000046","volume":"1","author":"M Matsuyama","year":"2010","unstructured":"Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, Sano H, et al. Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med. 2010;1:301\u20136.","journal-title":"Exp Ther Med"},{"key":"2535_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1245\/s10434-016-5534-3","volume":"24","author":"T Yoshida","year":"2017","unstructured":"Yoshida T, Kinoshita H, Fukui K, Matsuzaki T, Yoshida K, Mishima T, et al. Prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 2017;24:823\u201331.","journal-title":"Ann Surg Oncol"},{"key":"2535_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clgc.2021.04.002","volume":"19","author":"RK Jain","year":"2021","unstructured":"Jain RK, Skelton Iv WP, Pond GR, Naqvi M, Kim Y, Curran C, et al. Angiotensin blockade modulates the activity of PD1\/L1 inhibitors in metastatic urothelial carcinoma. Clin Genitourin Cancer. 2021;19:540\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"2535_CR12","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/j.clgc.2022.02.007","volume":"20","author":"G Motterle","year":"2022","unstructured":"Motterle G, Morlacco A, Giovannini G, Vecchiato E, Iafrate M, Calpista A, et al. Role of Renin-Angiotensin system blockers on BCG response in nonmuscle invasive, high risk bladder cancer. Clin Genitourin Cancer. 2022;20:e303\u2013e9.","journal-title":"Clin Genitourin Cancer"},{"key":"2535_CR13","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2535_CR14","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"2535_CR15","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstr\u00f6m PU, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810.","journal-title":"Lancet"},{"key":"2535_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc3858","volume":"15","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15:42\u201354.","journal-title":"Nat Rev Cancer"},{"key":"2535_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/nau.22267","volume":"32","author":"H Ito","year":"2013","unstructured":"Ito H, Taga M, Tsuchiyama K, Akino H, Yokoyama O. IPSS is lower in hypertensive patients treated with angiotensin-II receptor blocker: posthoc analyses of a lower urinary tract symptoms population. Neurourol Urodyn. 2013;32:70\u20134.","journal-title":"Neurourol Urodyn"},{"key":"2535_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"F Deshayes","year":"2005","unstructured":"Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"2535_CR19","doi-asserted-by":"crossref","unstructured":"Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int J Mol Sci. 2019;20:2505.","DOI":"10.3390\/ijms20102505"},{"key":"2535_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","volume":"277","author":"S Cagnol","year":"2010","unstructured":"Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence. FEBS J. 2010;277:2\u201321.","journal-title":"FEBS J"},{"key":"2535_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5:209.","journal-title":"Signal Transduct Target Ther"},{"key":"2535_CR22","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/JOE-17-0039","volume":"233","author":"KC Wang","year":"2017","unstructured":"Wang KC, Botting KJ, Zhang S, McMillen IC, Brooks DA, Morrison JL. Akt signaling as a mediator of cardiac adaptation to low birth weight. J Endocrinol. 2017;233:R81\u2013R94.","journal-title":"J Endocrinol"},{"key":"2535_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.","journal-title":"Cell Death Dis"},{"key":"2535_CR24","doi-asserted-by":"publisher","first-page":"1009.e19","DOI":"10.1016\/j.urology.2010.11.002","volume":"77","author":"S Shirotake","year":"2011","unstructured":"Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, et al. Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology. 2011;77:1009.e19\u201325.","journal-title":"Urology"},{"key":"2535_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1159\/000506775","volume":"98","author":"Y Sekino","year":"2020","unstructured":"Sekino Y, Han X, Babasaki T, Miyamoto S, Kitano H, Kobayashi G, et al. TUBB3 is associated with high-grade histology, poor prognosis, p53 expression, and cancer stem cell markers in clear cell renal cell carcinoma. Oncology. 2020;98:689\u201398.","journal-title":"Oncology"},{"key":"2535_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117\u201321.","journal-title":"Science"},{"key":"2535_CR27","doi-asserted-by":"publisher","first-page":"82ra37","DOI":"10.1126\/scitranslmed.3002227","volume":"3","author":"TN Burks","year":"2011","unstructured":"Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011;3:82ra37.","journal-title":"Sci Transl Med"},{"key":"2535_CR28","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"2535_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0723-0","volume":"11","author":"J Ye","year":"2019","unstructured":"Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019;11:137.","journal-title":"Clin Epigenetics"},{"key":"2535_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115837","volume":"217","author":"M Gekle","year":"2023","unstructured":"Gekle M, Dubourg V, Schwerdt G, Benndorf RA, Schreier B. The role of EGFR in vascular AT1R signaling: from cellular mechanisms to systemic relevance. Biochem Pharmacol. 2023;217:115837.","journal-title":"Biochem Pharmacol"},{"key":"2535_CR31","doi-asserted-by":"crossref","unstructured":"Moschetta-Pinheiro MG, Colombo J, Godoy BLV, Balan JF, Nascimento BC. Zuccari DAPC modulation of epithelial mesenchymal transition after AGTR-1 gene edition by Crispr\/Cas9 and Losartan treatment in mammary tumor cell line: a comparative study between human and canine species. Life (Basel). 2021;11:1427.","DOI":"10.3390\/life11121427"},{"key":"2535_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.cr.7290133","volume":"12","author":"W Xu","year":"2002","unstructured":"Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res. 2002;12:311\u201320.","journal-title":"Cell Res"},{"key":"2535_CR33","doi-asserted-by":"crossref","unstructured":"Mei J, Chu J, Yang K, Luo Z, Yang J, Xu J, et al. Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. J Immunother Cancer. 2024;12:e009327.","DOI":"10.1136\/jitc-2024-009327"},{"key":"2535_CR34","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.2147\/CMAR.S335543","volume":"13","author":"L Xiong","year":"2021","unstructured":"Xiong L, Wei Y, Zhou X, Dai P, Cai Y, Xu M, et al. AGTR1 inhibits the progression of lung adenocarcinoma. Cancer Manag Res. 2021;13:8535\u201350.","journal-title":"Cancer Manag Res"},{"key":"2535_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02363-z","volume":"41","author":"M Chen","year":"2024","unstructured":"Chen M, Wang H, Cui Q, Shi J, Hou Y. Dual function of activated PPAR\u03b3 by ligands on tumor growth and immunotherapy. Med Oncol. 2024;41:114.","journal-title":"Med Oncol"},{"key":"2535_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0178-3","volume":"8","author":"H Yamashita","year":"2019","unstructured":"Yamashita H, Kawasawa YI, Shuman L, Zheng Z, Tran T, Walter V, et al. Repression of transcription factor AP-2 alpha by PPAR\u03b3 reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis. 2019;8:69.","journal-title":"Oncogenesis"},{"key":"2535_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116169","volume":"171","author":"M Imenshahidi","year":"2024","unstructured":"Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171:116169.","journal-title":"Biomed Pharmacother"},{"key":"2535_CR38","doi-asserted-by":"crossref","unstructured":"Zhang D, Liu H, Yang B, Hu J, Cheng Y. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1\/MEK\/ERK\/STAT3\/PAX2 apoptotic pathways. Biosci Rep. 2019;39:BSR20190469.","DOI":"10.1042\/BSR20190469"},{"key":"2535_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80\u201391.","journal-title":"Semin Cancer Biol"},{"key":"2535_CR40","doi-asserted-by":"crossref","unstructured":"Kumar BH, Kabekkodu SP, Pai KSR. Structural insights of AKT and its activation mechanism for drug development. Mol Divers. 2025;29:5443\u201363.","DOI":"10.1007\/s11030-025-11132-7"},{"key":"2535_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1045521","volume":"12","author":"A Stulpinas","year":"2022","unstructured":"Stulpinas A, Sereika M, Vitkeviciene A, Imbrasaite A, Krestnikova N, Kalvelyte AV. Crosstalk between protein kinases AKT and ERK1\/2 in human lung tumor-derived cell models. Front Oncol. 2022;12:1045521.","journal-title":"Front Oncol"},{"key":"2535_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.","journal-title":"J Hematol Oncol"},{"key":"2535_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fphys.2016.00206","volume":"7","author":"ED Costa","year":"2016","unstructured":"Costa ED, Rezende BA, Cortes SF, Lemos VS. Neuronal nitric oxide synthase in vascular physiology and diseases. Front Physiol. 2016;7:206.","journal-title":"Front Physiol"},{"key":"2535_CR44","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/01.RES.83.12.1271","volume":"83","author":"CM Boulanger","year":"1998","unstructured":"Boulanger CM, Heymes C, Benessiano J, Geske RS, L\u00e9vy BI, Vanhoutte PM. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res. 1998;83:1271\u20138.","journal-title":"Circ Res"},{"key":"2535_CR45","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/0008-5472.CAN-17-1089","volume":"78","author":"P Ekambaram","year":"2018","unstructured":"Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, et al. The CARMA3-Bcl10-MALT1 signalosome drives NF\u03baB activation and promotes aggressiveness in angiotensin II receptor-positive breast cancer. Cancer Res. 2018;78:1225\u201340.","journal-title":"Cancer Res"},{"key":"2535_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/all.14019","volume":"75","author":"K Hayashi","year":"2020","unstructured":"Hayashi K, Kaminuma O, Nishimura T, Saeki M, Matsuoka K, Hiroi T, et al. LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation. Allergy. 2020;75:463\u20137.","journal-title":"Allergy"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02535-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:02:15Z","timestamp":1775426535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2535"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02535-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}